David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

The movie joined 2025 Netflix releases earlier this year, but after it made the top of NY Times ’ greatest films of the 21st ...

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study.

Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock’s Board of Directors as an independent director.

The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...

Scholar Rock's surprising success Apitegromab is an antibody that binds to another protein called myostatin, which normally works to limit muscle growth. It's being tested in the phase 3 Sapphire ...

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress Feb. 27, 2025 7:00 AM ET Scholar Rock Holding Corporation (SRRK) ...

Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...